Article:Multimorbidity in rheumatic conditions (5104809)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at Its title is Multimorbidity in rheumatic conditions and the publication date was 2016-11-01. The initial author is Helga Radner.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.

Converted JATS paper:

Journal Information

Title: Wiener Klinische Wochenschrift

Multimorbidity in rheumatic conditions

  • Helga Radner

Publication date (epub): 10/2016

Publication date (pmc-release): 10/2016

Publication date (ppub): /2016



In recent years, multimorbidity in rheumatic conditions has gained increasing attention. Rheumatologist care for an aging patient population with multiple diseases, therefore multimorbidity is the rule, not the exception. Owing to the high prevalence and the potential interaction of coexisting diseases, multimorbidity needs to be taken into account when treating patients with chronic inflammatory conditions. In this review we address the most prevalent comorbidities in patients with rheumatic conditions and their impact on important outcomes, such as physical function, quality of life, and mortality.


Over the last decade, interest in the concept of comorbidity and multimorbidity has increased [[1][3]]. This is likely due to the fact that clinicians are facing an aging population with multiple morbid conditions occurring in one individual. Especially for the rheumatologist, treating mainly chronic systemic inflammatory diseases, multimorbidity is the rule not the exception. The average rheumatoid arthritis (RA) patient has 1.6 additional conditions, increasing with age, disease duration, and/or disease activity.

Multimorbidity is defined as the “co-existence of two or more chronic diseases in the same individual.” It is a holistic concept, taking into account all potential interactions of co-existing diseases and its impact on the patient’s overall well-being [[4]]. For rheumatologists, understanding the complex role of multimorbidity is indispensable to provide safe, efficient, and optimal care of our patients.

Prevalence of multimorbidity in rheumatic conditions

Based on the published literature, the prevalence of multimorbidity in the general population is about 25 % [[1]], but prevalence estimates vary widely depending on the cohort’s age distribution and methods used to assess multimorbidity. The systemic inflammatory pathophysiological component of rheumatic conditions is inevitably accompanied by multiple other conditions in one individual and, therefore, multimorbid patients are highly prevalent in rheumatology [[5]]. Approximately two third of patients with RA are considered to be multimorbid. Studies have shown that certain morbidities co-exist because of a shared risk factor profile leading to high co-occurrence rates, such as smoking, obesity, or a sedentary lifestyle. Some studies describe an association of multimorbidity with female gender and low socioeconomic status, but only a few studies have investigated the causes and risk factors for multimorbid patients in detail [[1], [6]]. Data on prevalence rates of multimorbidity mainly exist for RA patients, whereas for other rheumatic conditions such as psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), or ankylosing spondylitis (AS), only limited data are available. Also for other chronic inflammatory conditions such as inflammatory bowel disease (IBD), only a few studies are available addressing the incidence and importance of multimorbidity [[7]]. The highest prevalence rates of cardiovascular diseases, depression, and osteoporosis can be observed in RA patients [[8], [9]]. The prevalence rates of the main conditions for distinct rheumatic conditions are listed in Table 1.Table 1

Prevalence of different morbid conditions in inflammatory rheumatic conditions

Morbid conditions RA (%)[[8], [50]] SpA (%)[[51]] SLE (%)[[18], [52][56]]
Cardiovascular disease 6 3 6–10
Cardiovascular risk factors
HypertensionDyslipidemiaDiabetes 403214 34279 4036–6011
Osteoporosis 30 13 23
Cancer (any solid) 5 3 3.2
Depression 15 11 46

RA rheumatoid arthritis, SLE systemic lupus erythematosus, SpA spondylarthropathies


Rheumatic patients are at increased risk of developing certain malignancies, mainly lymphoproliferative disorders in RA, SLE, or Sjoegren syndrome [[10], [11]]. For other malignancies such as colorectal cancer, a decreased risk can be observed, possibly due to chronic use of NSAIDs.

Over the last few years, increasing evidence was found demonstrating there is no increased risk of most cancers for RA patients on tumor necrosis factor (TNF)-inhibitor therapy compared with conventional disease-modifying anti-rheumatic drug (DMARD) therapy such as methotrexate or leflunomide, and that the risk of cancer did not increase over time for patients on TNF inhibitor therapy [[12]]. Furthermore, in retrospective case control studies, the risk of cancer recurrence in RA patients treated with TNF inhibitors was similar to that for TNF-naïve patients [[13], [14]].

Cardiovascular disease

Owing to the chronic inflammatory character, a shared risk profile such as smoking or physical inactivity and a higher risk of cardiovascular (CV) morbidity and mortality can be observed in many rheumatic conditions such as RA or PsA [[15][18]]. Young women with SLE may be up to 50 times more likely to suffer from myocardial infarction compared with population-based controls [[19]]. The rate of CVD in patients with AS is not fully clear with some studies showing a higher prevalence compared with the general population [[20], [21]], losing statistical significance after adjusting for NSAID use [[22]]. The stringent control of disease activity plays a central role in minimizing CV risk as it leads to a reduction of inflammation. It has been shown that despite disease control, DMARDs can also improve lipid profile [[23], [24]] or diabetes [[25]], which reduces the risk of CV outcomes. The European League Against Rheumatism (EULAR) has acknowledged the importance of CV disease in inflammatory arthritis and has provided recommendations for CV risk assessment and management [[26]].

Osteoporosis and pulmonary disease

A higher prevalence of osteoporosis can be observed in patients with rheumatic conditions. The increased risk is mainly induced by glucocorticoid therapy but is also due to immobility and inflammation [[27]]. Especially in SLE patients, an increased incidence of osteoporosis and symptomatic fractures can be observed, which is mainly related to steroid therapy, disease duration, and disease severity [[28]]. The increased risk of major fracture in RA patients is taken into account in various osteoporosis risk assessment tools [[29]].

Recent studies demonstrated an increased prevalence and risk of mortality due to respiratory disease in RA patients independent of smoking [[30]].

Impact of multimorbidity on important outcomes

Owing the increasing prevalence of multimorbidity, the clinical but also health economic implications have become more prominent, with an exponential rise in costs with increasing number of concomitant chronic conditions [[31]]. Multimorbidity can impact therapeutic decisions as well as important clinical outcomes.


It is known from previous studies that multimorbid patients with RA are potentially undertreated for their concomitant disease [[32]], which might have a negative effect on RA disease activity. Furthermore, we were able to show different treatment patterns in multimorbid RA patients, with a significant lower odds of biological DMARD use in multimorbid RA patients, even if needed because of persisting high disease activity. This is of special importance as it was shown that a more intensive treatment of rheumatic conditions leads to a significant improvement of co-existing conditions, such as CV disease or metabolic syndrome [[33], [34]].

Guidelines such as “treat to target” or EULAR treatment recommendations were developed in order to achieve optimal therapeutic outcomes in patients with rheumatic conditions. Such strategies based on systematic literature reviews and expert opinion were developed for patients with a single rheumatic condition only and therefore might overlook multimorbidity [[35]]. Owing to the given inclusion and exclusion criteria, clinical trials exclude multimorbid patients, which limits the generalizability of results and therefore makes it difficult to apply recommendations to daily routine patients. Further studies are needed to assess the effectiveness and safety of DMARD therapy in the subgroup of multimorbid rheumatic patients.

Disease activity

It was shown that with an increasing number of co-existing morbidities per patients, a higher activity of the rheumatic condition could be observed. Multimorbid patients are less likely to achieve treatment targets such as remission or low disease activity. We found that even after adjusting for important covariates such as age, disease duration, or number of previous DMARDs, the odds of achieving remission decreased by 28 % per additional morbidity 1 year after DMARD initiation [[36][38]]. This might be due to the interaction of co-existing diseases, polypharmacy, or the tendency to undertreat multimorbid patients [[39]].

Furthermore, measures of disease activity developed to assess treatment targets, such as the disease activity score (DAS) or the clinical disease activity index (CDAI), comprise patient-reported outcomes such as patient global assessment of disease activity (PGA), which might be directly affected by multimorbidity. In a recent study of RA patients we found an almost linear increase of PGA with increasing number of morbidities per patient, independent of RA disease activity (Fig. 1a; [[40]]).Fig. 1

Impact of multimorbidity on disease-related outcomes: a increase of patients’ global assessment of disease activity with rising number of morbid conditions per patients; b physical impairment increasing with increasing number of morbidities

Physical function and quality of life

The burden of multimorbidity has a negative impact on important outcomes such as health-related quality of life (HRQoL) or physical function, independent of disease activity. Even for RA patients in remission, a significant increase of physical impairment with an increasing number of concomitant diseases was found (Fig. 1b), underlining the overall burden of multimorbidity not only for the individual patient but also for society because of higher rates of work disability [[41][43]]. In population-based studies it was shown that the negative impact of multimorbidity on function and HRQol is highest in patients having a rheumatic condition as part of their multimorbidity [[44]].


Over the last decade after introducing biological DMARD therapy, an improvement in disease activity and increasing remission rates were achieved. Nevertheless, despite optimum treatment strategies, a so-called mortality gap can be observed, showing a decrease in mortality in the general population whereas mortality rates in patients with rheumatic conditions remain high or even show a trend of increasing over time [[45]]. Radovits et al. showed that concomitant conditions are the strongest predictor of mortality [[46]]. In register studies of RA patients, cardiovascular and respiratory mortality were increased [[47], [48]]; for other rheumatic conditions, higher mortality due to cancer was found [[49]].


In patients with chronic inflammatory rheumatic conditions, multimorbidity is highly prevalent with an impact on important clinical outcomes such as disease activity, physical function, or mortality. By understanding and implementing the concept of multimorbidity, quality of care and clinical outcomes can be improved.


Open access funding provided by Medical University of Vienna.


  1. K BarnettSW MercerM NorburyEpidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional studyLancet20123809836374310.1016/S0140-6736(12)60240-222579043
  2. C DiederichsK BergerDB BartelsThe measurement of multiple chronic diseases – a systematic review on existing multimorbidity indicesJ Gerontol A Biol Sci Med Sci201066330131121112963
  3. M FortinM StewartME PoitrasA systematic review of prevalence studies on multimorbidity: toward a more uniform methodologyAnn Fam Med201210214215110.1370/afm.133722412006
  4. H RadnerK YoshidaJS SmolenMultimorbidity and rheumatic conditions-enhancing the concept of comorbidityNat Rev Rheumatol201410425225610.1038/nrrheum.2013.21224418765
  5. N SattarIB McInnesVascular comorbidity in rheumatoid arthritis: potential mechanisms and solutionsCurr Opin Rheumatol200517328629210.1097/01.bor.0000158150.57154.f915838238
  6. AA UijenEH van de LisdonkMultimorbidity in primary care: prevalence and trend over the last 20 yearsEur J Gen Pract200814Suppl 1283210.1080/1381478080243609318949641
  7. AL RomanF MunozComorbidity in inflammatory bowel diseaseWorld J Gastroenterol201117222723273310.3748/wjg.v17.i22.272321734780
  8. M DougadosM SoubrierA AntunezPrevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)Ann Rheum Dis2014731626810.1136/annrheumdis-2013-20422324095940
  9. KL GronLM OrnbjergML HetlandThe association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA programClin Exp Rheumatol201432686987725327997
  10. S BernatskyJF BoivinL JosephAn international cohort study of cancer in systemic lupus erythematosusArthritis Rheum20055251481149010.1002/art.2102915880596
  11. AL SmittenTA SimonMC HochbergA meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritisArthritis Res Ther2008102R4510.1186/ar240418433475
  12. J AsklingRF van VollenhovenF GranathCancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?Arthritis Rheum200960113180318910.1002/art.2494119877027
  13. P RaaschouT FrisellJ AsklingTNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort studyAnn Rheum Dis201574122137214310.1136/annrheumdis-2014-20574525107559
  14. A StrangfeldF HierseR RauRisk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBITArthritis Res Ther2010121R510.1186/ar290420064207
  15. A JamnitskiD SymmonsMJ PetersCardiovascular comorbidities in patients with psoriatic arthritis: a systematic reviewAnn Rheum Dis201372221121610.1136/annrheumdis-2011-20119422532629
  16. HG RatermanH LevelsAE VoskuylHDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximabAnn Rheum Dis201372456056510.1136/annrheumdis-2011-20122822589377
  17. DH SolomonGC CurhanEB RimmCardiovascular risk factors in women with and without rheumatoid arthritisArthritis Rheum200450113444344910.1002/art.2063615529391
  18. SG MurrayJ YazdanyR KaiserCardiovascular disease and cognitive dysfunction in systemic lupus erythematosusArthritis Care Res (Hoboken)20126491328133310.1002/acr.2169122549897
  19. S ManziEN MeilahnJE RairieAge-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham StudyAm J Epidemiol1997145540841510.1093/oxfordjournals.aje.a0091229048514
  20. MM NielenAM van SijlMJ PetersCardiovascular disease prevalence in patients with inflammatory arthritis, diabetes mellitus and osteoarthritis: a cross-sectional study in primary careBmc Musculoskelet Disord20121315010.1186/1471-2474-13-15022906083
  21. MT NurmohamedI van der Horst-BruinsmaWP MaksymowychCardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insightsCurr Rheumatol Rep201214541542110.1007/s11926-012-0270-622791397
  22. I EssersC StolwijkA BoonenAnkylosing spondylitis and risk of ischaemic heart disease: a population-based cohort studyAnn Rheum Dis201675120320910.1136/annrheumdis-2014-20614725362044
  23. SJ MorrisMC WaskoJL AntoheHydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patientsArthritis Care Res (Hoboken)201163453053410.1002/acr.2039321452265
  24. A JamnitskiIM VismanMJ PetersBeneficial effect of 1‑year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA studyAnn Rheum Dis201069111929193310.1136/ard.2009.12759720498216
  25. DH SolomonE MassarottiR GargAssociation between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasisJAMA2011305242525253110.1001/jama.2011.87821693740
  26. MJ PetersDP SymmonsD McCareyEULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritisAnn Rheum Dis201069232533110.1136/ard.2009.11369619773290
  27. TP van StaaP GeusensJW BijlsmaClinical assessment of the long-term risk of fracture in patients with rheumatoid arthritisArthritis Rheum200654103104311210.1002/art.2211717009229
  28. IE BultinkWF LemsLupus and fracturesCurr Opin Rheumatol201628442643210.1097/BOR.000000000000029026978130
  29. JA KanisA OdenH JohanssonFRAX and its applications to clinical practiceBone200944573474310.1016/j.bone.2009.01.37319195497
  30. JA SparksSC ChangKP LiaoRheumatoid arthritis and mortality among women during 36 years of prospective follow-up: results from the Nurses’ Health StudyArthritis Care Res (Hoboken)201568675376210.1002/acr.22752
  31. JL WolffB StarfieldG AndersonPrevalence, expenditures, and complications of multiple chronic conditions in the elderlyArch Intern Med2002162202269227610.1001/archinte.162.20.226912418941
  32. TE TomsVF PanoulasKM DouglasStatin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?Ann Rheum Dis201069468368810.1136/ard.2009.11571719854705
  33. L CostaF CasoM AttenoImpact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patientsClin Rheumatol201433683383923959447
  34. WG DixonKD WatsonM LuntReduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics RegisterArthritis Rheum20075692905291210.1002/art.2280917763428
  35. CM BoydJ DarerC BoultClinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performanceJAMA2005294671672410.1001/jama.294.6.71616091574
  36. VK RanganathP MaranianDA ElashoffComorbidities are associated with poorer outcomes in community patients with rheumatoid arthritisRheumatology (Oxford)201352101809181710.1093/rheumatology/ket22423813577
  37. H RadnerK YoshidaM FritsThe impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugsRheumatology (Oxford)201554112076208410.1093/rheumatology/kev23926163688
  38. L EderA ThavaneswaranV ChandranObesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritisAnn Rheum Dis201574581381710.1136/annrheumdis-2013-20444824431392
  39. H RadnerK YoshidaI HmamouchiTreatment patterns of multimorbid patients with rheumatoid arthritis: results from an international cross-sectional studyJ Rheumatol20154271099110410.3899/jrheum.14153426034147
  40. H RadnerK YoshidaSK TedeschiM FritsC IannaconeN ShadickM WeinblattD AletahaJS SmolenDH SolomonDifferent perception of disease activity in Multimorbid rheumatoid arthritis patients [abstract]Arthritis Rheum201567Suppl 10abstract 3258
  41. I RuppHC BoshuizenCE JacobiComorbidity in patients with rheumatoid arthritis: effect on health-related quality of lifeJ Rheumatol2004311586514705219
  42. H RadnerJS SmolenD AletahaComorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritisRheumatology (Oxford)201050238138810.1093/rheumatology/keq33421036875
  43. H RadnerJS SmolenD AletahaImpact of comorbidity on physical function in patients with rheumatoid arthritisAnn Rheum Dis200969353654110.1136/ard.2009.11843019825848
  44. E LozaJA JoverL RodriguezMultimorbidity: prevalence, effect on quality of life and daily functioning, and variation of this effect when one condition is a rheumatic diseaseSemin Arthritis Rheum200938431231910.1016/j.semarthrit.2008.01.00418336872
  45. SE GabrielK MichaudEpidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseasesArthritis Res Ther200911322910.1186/ar266919519924
  46. BJ RadovitsJ FransenS Al ShammaExcess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritisArthritis Care Res (Hoboken)201062336237010.1002/acr.2010520391482
  47. BR EnglandH SaylesK MichaudCause-specific mortality in male US veterans with rheumatoid arthritisArthritis Care Res (Hoboken)2016681364510.1002/acr.2264226097231
  48. JA SparksSC ChangKP LiaoRheumatoid arthritis and mortality among women during 36 years of prospective follow-up: results from the nurses’ health studyArthritis Care Res (Hoboken)201668675376210.1002/acr.2275226473946
  49. CC MokCL KwokLY HoLife expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, ChinaArthritis Rheum20116351182118910.1002/art.3027721391198
  50. B HauserPL RichesJF WilsonPrevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritisRheumatology (Oxford)201453101759176610.1093/rheumatology/keu16224764264
  51. A MoltoA EtchetoD van der HeijdePrevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA studyAnn Rheum Dis20167561016102310.1136/annrheumdis-2015-20817426489703
  52. M Abu-ShakraDD GladmanMB UrowitzMalignancy in systemic lupus erythematosusArthritis Rheum19963961050105410.1002/art.17803906258651970
  53. K AlmehedH Forsblad d’EliaG KvistPrevalence and risk factors of osteoporosis in female SLE patients-extended reportRheumatology (Oxford)20074671185119010.1093/rheumatology/kem10517500075
  54. FG NeryEF BorbaVS VianaPrevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodiesProg Neuropsychopharmacol Biol Psychiatry200832369570010.1016/j.pnpbp.2007.11.01418077068
  55. JM SabioJA Vargas-HitosN Navarrete-NavarretePrevalence of and factors associated with hypertension in young and old women with systemic lupus erythematosusJ Rheumatol20113861026103210.3899/jrheum.10113221406497
  56. K TseliosC KoumarasDD GladmanDyslipidemia in systemic lupus erythematosus: just another comorbidity?Semin Arthritis Rheum201645560461010.1016/j.semarthrit.2015.10.01026711309
The underlying source XML for this text is taken from The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as osteoporosis.